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Abstract
Background: ID proteins are dominant negative inhibitors of basic helix-loop-helix transcription factors that have
multiple functions during development and cellular differentiation. Ectopic (over-)expression of ID1 extends the
lifespan of primary human epithelial cells. High expression levels of ID1 have been detected in multiple human
malignancies, and in some have been correlated with unfavorable clinical prognosis. ID1 protein is localized at the
centrosomes and forced (over-)expression of ID1 results in errors during centrosome duplication.
Results: Here we analyzed the steady state expression levels of the four ID-proteins in 18 tumor cell lines and
assessed the number of centrosome abnormalities. While expression of ID1, ID2, and ID3 was detected, we failed
to detect protein expression of ID4. Expression of ID1 correlated with increased supernumerary centrosomes in
most cell lines analyzed.
Conclusions: This is the first report that shows that not only ectopic expression in tissue culture but endogenous
levels of ID1 modulate centrosome numbers. Thus, our findings support the hypothesis that ID1 interferes with
centrosome homeostasis, most likely contributing to genomic instability and associated tumor aggressiveness.
Background
The inhibitor of DNA-binding (ID) proteins, ID1-4, are
negative regulators of basic Helix-Loop-Helix (bHLH)
transcription factors. They lack the basic domain neces-
sary for DNA-binding. By forming DNA-binding incom-
petent heterodimers with bHLH factors they inhibit
transcription of target genes. Various cellular processes
are regulated by individual ID-proteins: Inhibition of
cellular differentiation by interference with differentia-
tion-specific bHLH and non-bHLH transcription factors
[1], extension of cellular life span [2-4], regulation of
angiogenesis [5,6] as well as cardiac development [7]
and maintenance of the embryonic stem cell phenotype
[8]. ID expression is deregulated in many tumors,
including cervical cancer [9], melanoma [10], pancreatic
cancer [11], squamous cell carcinoma of the esophagus
[12] and in thyroid cancer [13]. In some tumors ID-
expression is associated with poor clinical prognosis, e.g.
in ovarian cancer, in cervical cancer, in prostate cancer,
and in breast cancer [9,14-17]. Taken together, these
data imply an oncogenic role for ID proteins.
Ectopic expression of ID1 rapidly leads to the accu-
mulation of supernumerary centrosomes in primary
human keratinocytes [18], induction of tetraploidy in
telomerase-immortalized nasopharyngeal epithelial cells
[19], and induction of chromosomal instability through
deregulation of APC/Cdh1 in prostate epithelial cells
[20]. A fraction of ID1, but not of the other ID proteins,
is localized at centrosomal structures. ID1 is the only ID
family member that shows a clear association with nor-
mal and supernumerary centrosomes throughout the
cell cycle [18]. No centrosomal localization can be
detected for ID2-4, irrespective of the cell cycle or cen-
trosome duplication status of the cell ([18] and data not
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centrosomal changes are deregulation of the centroso-
mal proteasome [21] and stabilization of aurora kinase
A [19]. Centrosomes are the microtubule organizing
centers (MOC) of the cell and consist of two centrioles
surrounded by pericentriolar material containing differ-
ent coiled-coil proteins, e.g. pericentrin and ninein
[22-25]. Centrosome duplication is a critical event dur-
ing mitosis, as it must only happen once to ensure the
formation of a bipolar mitotic spindle and equal segre-
gation of chromosomes during mitosis. Duplication is
initiated at the G1-S-phase transition and is controlled
by CDK2-Cyclin E/A activity [24]. Furthermore, phos-
phorylation of pRB seems to be necessary followed by
the activity of E2F transcription factors [26]. Centro-
some abnormalities are found in neurodegenerative pro-
cesses as well as in autoimmune diseases, but most
frequently they are observed in human malignancies
(reviewed in [22,27]). In normal cells centrosome defects
lead to G1 arrest of the cell via p53 activation [28].
Tumor cells with mutated p53 lack this mechanism and
can still undergo mitosis and thereby accumulate cen-
trosome defects [29]. Furthermore, various cellular and
viral oncogenes can induce centrosome abnormalities
independent of p53 [18,30-32]. Supernumerary centro-
somes lead to the formation of abnormal multipolar
mitoses and may ultimately induce aneuploidy [33-35].
Here, we analyzed endogenous ID expression levels in
various (tumor) cell lines. By assessing the number of
c e n t r o s o m e sw es h o wh e r et h a th i g he n d o g e n o u sI D 1
expression, but not that of the other ID proteins, is
associated with a higher rate of abnormal centrosomes.
This lends further support to the hypothesis that ID1
interferes with centrosomal function and can promote a
more aggressive tumor phenotype.
Results
Ectopic expression of ID1 in primary human cells
results in accumulation of supernumerary centrosomes
in these cells [18]. High expression levels of the ID-pro-
teins have been observed in various proliferating tissue
types [36]. As there are several, partly contradictory
reports about the expression levels of the four ID-pro-
teins in primary tumor cells and cell lines, we analyzed
18 established (tumor) cell lines for endogenous ID pro-
tein expression levels in proliferating cells.
ID proteins are differentially expressed in tumor cell lines
Protein expression levels of the four ID-proteins were
analyzed in proliferating cells using standard Western
blotting technique. Cell cycle analysis confirmed similar
cell cycle distribution of the different cell lines (Addi-
tional File 1). ID protein expression was normalized to
GAPDH-expression. Expression of ID1 was readily
detectable in all cervical cancer cell lines, in HaCaT, in
the colon cancer line HCT-15 as well as in Jurkat (lym-
phocytic leukemia) (Figure 1A). Intermediate expression
of ID1 could be detected in the remaining leukemic cell
lines and in two breast cancer cell lines, T47-D and
MDA-MB453, whereas MCF-7 and MDA-MB468 only
showed very low ID1 expression. ID2 protein expression
could be detected in most cell lines (Figure 1B). Only
CaSki, a cervical cancer cell line, H-2171 (SCLC), and
the osteosarcoma cell line U2OS did not express ID2 in
remarkable levels. In contrast higher ID3 expression was
only detectable in a small number of cells, i.e. in Jurkat,
HaCaT, HeLa, and C33A cells (Figure 1C). ID4 protein
was undetectable in all examined cell lines (Figure 1D)
confirming earlier reports that ID4 is mainly expressed
in neural tissues [37].
ID-mRNA expression does not correlate with protein
expression
To compare mRNA expression of the ID proteins with
protein expression, quantitative real time PCR (qRT-
PCR) was performed on selected cell lines using ID-spe-
cific primer pairs. We observed different ID mRNA
expression patterns as compared to ID protein expres-
sion patterns (Figure 2). ID1 mRNA expression could be
detected at similar levels in all cell lines (Figure 2A).
ID2 mRNA expression was readily detectable in all cell
lines. Here, only Jurkat seemed to express lower levels
of ID2 mRNA, which is in contrast to the relatively high
ID2 protein expression in these cells (Figure 2B). ID3
mRNA expression correlated with the ID3 protein
expression levels in all cell lines but HCT-15, where the
highest mRNA-expression but low protein expression of
ID3 was seen (Figure 2C). Most cell lines analyzed
showed undetectable ID4 mRNA levels, a finding corre-
lating with non-detectable ID4 protein expression in
these cells. Surprisingly, HaCaT cells express high levels
of ID4 mRNA, which did not translate into higher ID4
protein levels (Figure 2D).
Analysis of centrosome number
To address the question whether endogenous ID1 can
contribute to accumulation of supernumerary centro-
somes, as has been reported for ectopic ID1 expression,
the number of centrosomes was determined using
immunofluorescence microscopy. A monoclonal anti-
body against g-tubulin, a component of the pericentrio-
lar matrix was used to visualize centrosomes. Only cells
with one nucleus were analyzed and n > 2 centrosomes
per cells were counted as having supernumerary centro-
somes. We know from previous experiments that the
rate of abnormal centrosomes is approximately 2% in
human foreskin keratinocytes. Therefore we assumed a
rate of centrosomal abnormalities of > 2% as aberrant.
Analysis of centrosome number in leukemic cells
showed the highest percentage of cells with aberrant
centrosomes in Jurkat, followed by HL-60 and U937.
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Figure 1 Endogenous ID expression in different cell lines. A) Expression analysis of ID proteins in leukemic cells. B) Expression of ID proteins
in cervical cancer cells. C) Expression of ID proteins in breast cancer cells. D) Expression of ID proteins in other epithelial cells. Cells were grown
up to 70% confluence and harvested for protein. Protein extracts (10 μg) were then submitted to western blot analysis. Primary antibodies used
were anti-ID1, anti-ID2, anti-ID3 and anti-ID4, GAPDH expression as loading control. Examined cell lines and their characteristics are summarized
in Additional File 3.
Figure 2 ID mRNA expression in 5 selected cell lines, assessed by qRT-PCR; ID-specific primers were used, shown is the mean of at least
two independent experiments, bars represent standard deviation; relative values (2
-ΔΔCt) were calculated using SiHa cells as control cell line,
therefore ID mRNA expression was first related to GAPDH mRNA expression in each cell line (ΔCtq), following relation to ID mRNA expression in
SiHa cells (ΔΔCt), then submitted to the above mentioned term; A) ID1 mRNA; B) ID2 mRNA; C) ID3 mRNA; D) ID4 mRNA.
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Page 3 of 11Kazumi cells had the lowest percentage of supernumer-
ary centrosomes (Figure 3A &3G). All cervical cancer
cells showed a higher percentage of aberrant centro-
somes, ranging from 6.5% (SiHa) to 11% (C33A) (Figure
3B &3E). Breast cancer cells showed similar centrosome
abnormalities with exception of T47-D (Figure 3C, F
&3H). The other tested cell lines showed very heteroge-
neous centrosome numbers (Figure 3D). The highest
numbers of abnormal centrosomes (>9%) were detected
in Jurkat, T 47-D, C33A and HeLa cells (summarized in
Table 1). An intermediate frequency could be observed
in HaCaT, CaSki and HCT-15 with 8.7% (STD ± 1.9),
8.8% (STD ± 1.1) and 8.3% (STD ± 3.3) of supernumer-
ary centrosomes. The remaining cell lines showed a
lower number of abnormal centrosomes ranging from
6.6% (± 2.0) in MDA-MB453 to 2.9% (± 0.2) in Kasumi-
1 cells (Table 1). Higher ID1 expression correlated with
more pronounced centrosomal colocalization (Addi-
tional File 2). Centrosome number did not influence the
rate of mono- or multipolar mitoses (Table 1). The
group of David Pellman recently proposed a direct
mechanism by which supernumerary centrosome could
induce chromosomal instability: Using long-term live-
cell imaging Ganem and colleagues could demonstrate
that cells with multiple centrosomes rarely undergo
multipolar cell divisions, but routinely undergo bipolar
cell divisions. Furthermore, the authors could convin-
cingly show that extra centrosomes alone are sufficient
to promote chromosome missegregation during bipolar
cell division, and propose this to be the mechanism and
the common underlying cause of CIN in human cancer
[38].
High ID1 expression correlates with increased
centrosomal abnormalities
We have previously reported accumulation of supernu-
merary centrosomes in cells ectopically expressing ID1
[18,21]. No influence of ID2, ID3 or ID4 was detected
then. Our findings here were very suggestive that endo-
genous ID1 expression might also influence centrosomal
homeostasis in various cancer cell lines. Comparison of
ID1 expression and the number of centrosomal abnorm-
alities showed a clear and significant correlation of high
ID1-expression with an increased number of centrosome
abnormalities (Figure 4A) (Spearman’s rank correlation
coefficient p = 0.66804). Surprisingly, not only ID1
expression but also ID3 expression correlated with cen-
trosome abnormalities (Spearman’s coefficient p =
0.61976), whereas ID2 and ID4 did not. Similarly, colo-
calization of ID1 with centrosomes (i.e. with g-tubulin)
was more obvious in leukemic cells expressing higher
levels of endogenous ID1 (Additional file 1).
Taken together, elevated endogenous ID1 expression,
as seen in diverse cancer cell lines, is associated with an
increased number of centrosome abnormalities. Further-
more we have shown here that all ID proteins, except
ID4, are expressed in cancer cell lines and that protein
expression does not strictly correlate with mRNA
expression, most likely due to post-translational modifi-
cations and/or ID protein stability and dynamics. Our
findings confirm a role of ID proteins in the regulation
of centrosome duplication and raise the question of how
protein expression of the ID-proteins beyond transcrip-
tion is regulated.
Discussion
Although it has been reported that ectopic expression of
ID1 but not ID2-4 leads to rapid induction of cells with
supernumerary centrosomes [18,19,21] one cannot rule
out that this is due to the experimental conditions. We
therefore analyzed ID expression in different cell types
using immunoblot and real time PCR to correlate endo-
genous ID expression with centrosome abnormalities.
Apart from ID2, which showed a uniform expression
pattern in breast cancer and leukemic cells, we did not
detect a clear tissue specific expression pattern of the
IDs. ID2 is induced in the course of normal granulopo-
esis [39,40]. ID2 can also be induced by myc through
direct promoter activation [41]. Both leukemic cell lines,
HL-60 and U937, express myc at high levels, which
might explain high ID2 expression in these cells [42]. In
addition, ID2 can be induced by HIF-1 and HIF-2
(Hypoxia induced factors), which might contribute to
ID2 expression in breast cancer cells [43].
ID3 protein was expressed in a minority of cells, and
ID4 protein expression was undetectable in all cell lines
analyzed, confirming earlier results [37]. Whether ID4
positively influences tumor growth is still not completely
understood. Recent studies revealed that the ID4 gene
can be silenced through promoter hypermethylation in
various tumors [44-48], suggesting a tumor suppressive
role. On the other hand ID4 was identified as an
upstream regulator of BRCA1 in breast and ovarian can-
cer, and more aggressive breast cancer types showed
higher ID4 expression [49]. Additionally, activating
translocations of ID4 have been detected in some
patients and a subset of acute lymphoblastic leukemia
[50-52].
ID1 protein expression was readily detectable in most
of the cell lines analyzed. Expression was independent of
cell cycle distribution or underlying mutations. Since
cells were cultured simultaneously under the same con-
ditions, differential induction of ID1 by growth factors
from the culture medium is also unlikely. Other factors
e.g. proteasomal degradation, RNA stability, microRNAs,
posttranscriptional and posttranslational modifications,
or gene amplification might regulate ID1 expression.
The observed differences between ID protein and
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Page 4 of 11Figure 3 Assessment of centrosome numbers in established cell lines. Quantitative analysis of centrosome abnormalities and abnormal
mitoses depicted as mean of at least 3 independent experiments, bars represent standard deviation. A) Percentage of cells with supernumerary
centrosomes in leukemic cells. B) Percentage of cells with supernumerary centrosomes in cervical cancer cells. C) Percentage of cells with
supernumerary centrosomes in breast cancer cells. D) Percentage of cells with supernumerary centrosomes in other epithelial cells. E-H:
Immunofluorescence analysis. Centrosomes were visualized using g-tubulin antibody (green); nuclei were visualized using Hoechst 33258
(blue); for each group of cell lines representative examples of normal (left picture) and abnormal (right picture) centrosome numbers are shown;
E) Cell lines with a high rate of centrosomal abnormalities, e.g. C33A F) Cell lines with an intermediate rate of centrosomal abnormalities, e.g.
MDA-MB468 G) Cell lines with a low rate of centrosome abnormalities, e.g. Kasumi-1 H) Cell lines with a high number of abnormal centrosomes
and mitoses, e.g. T47-D.
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altered soon after transcription or after translation. ID1,
ID2 and ID3 are degraded via the ubiquitin-proteasome
complex while ID4 seems to be eliminated through
other pathways [53-55]. The half-life of ID proteins,
namely ID1 and ID3 is relatively short, depending on
the cell type and cell cycle status. It ranges from 30 to
60 minutes [53-55]. Additionally the biological activity
of ID2 and ID3 can be altered by phosphorylation,
which occurs in late G1 and alters the binding specifi-
city and the stability of these ID proteins [56,57]. By
altering the proteasome activity or by accelerating ubi-
quitination ID protein degradation could be promoted
[58]. Intracellular miRNAs or siRNAs might trigger ID
mRNA degradation or inhibit translation. Thus, to mea-
sure biological activity of the IDs and to further analyze
their role in tumor development, protein expression
should be determined rather than mRNA expression.
We show here that elevated endogenous ID1 expres-
sion levels correlate with the accumulation of abnormal
centrosomes. Interestingly, a statistical correlation
between ID3 expression and ID1 expression and there-
fore between ID3 and centrosomal abnormalities was
found, which might be due to co-regulation of ID1 and
ID3 [59]. Centrosome duplication is orchestrated by
cyclins, cyclin-dependent kinases and their inhibitors
[60], and loss of the latter results in centriole over dupli-
cation [61]. As ID proteins influence members of the
cyclin-inhibiting Cip and Kip factors, e.g. p21
Waf1/Cip1
and p27
Kip1, one might assume that ID1 induces centro-
some abnormalities by inhibiting p21
Waf1/Cip1.T h i s
seems unlikely, as only ectopic expression of ID1 leads
to centrosomal abnormalities, whereas all ID proteins
regulate p21
Waf1/Cip1 promoter activity [18]. Other
(proto)oncogenes such as myc can induce centrosomal
abnormalities [21,62,63]. The high-risk human papilloma
virus (HPV) E6 and E7 oncoproteins lead to genomic
instability and induce abnormal centrosomes [64]. Cervi-
cal cancer is most often caused by infection with high-
risk HPV [65]. All cervical cancer cell lines analyzed
showed high levels of abnormal centrosomes. Interest-
ingly, the highest rate of supernumerary centrosomes
was detected in C33A cells, which are HPV negative.
Therefore, another mechanism must contribute to accu-
mulation of abnormal centrosomes in these cells, e.g.
high expression levels of ID1.
One mechanism that ID1 can deregulate centrosome
duplication is by regulating the activity of the centroso-
mal proteasome. This is in part mediated through inter-
action of ID1 with S5a, a subunit of the 26S
proteasome. ID1 and S5A are both located at centroso-
mal structures. Ectopic expression of S5a normalizes
ID1-induced centrosome abnormalities, and depletion of
S5a leads to a similar accumulation of supernumerary
centrosomes without tetraploidization [21]. Develop-
ment of centrosomal alterations and cell aneuploidy has
been linked to overexpression of the centrosomal kinase
Aurora A [20]. Indeed, it has been shown that ID1
Table 1 Summary of ID expression analysis, centrosome abnormalities and abnormal mitoses.
Cell Line ID1 ID2 ID3 ID4 % cells with n
>2
centrosomes
% mitoses % abnormal
mitoses
C33A + + (+) - 11.2 (± 1.8) 6.8 (± 4.5) 1.3 (± 0.9)
JURKAT + ++ ++ - 10.5 (± 1.1) 3.3 (± 0.5) 0.9 (± 0.5)
T47D (+) ++ - - 9.7 (± 1.8) 5.5 (± 1.7) 1.2 (± 0.2)
HeLa + (+) (+) - 9.3 (± 0.9) 6.9 (± 0.2) 0.8 (± 0.2)
CaSki + - - - 8.8 (± 1.1) 11.0 (± 4.7) 3.8 (± 1.2)
HaCaT + (+) (+) - 8.7 (± 1.9) 4.2 (± 1.6) 1.7 (± 0.1)
HCT-15 + + (+) - 8.3 (± 3.3) 1.2 (± 1.6) 0.3 (± 0.6)
MDA-MB-453 (+) (+) (+) - 6.6 (± 2.0) 3.2 (± 0.2) 1.2 (± 0.2)
MCF-7 - (+) - - 6.5 (± 2.3) 4.3 (± 1.4) 0.5 (± 0.2)
SiHa + (+) (+) - 6.5 (± 0.4) 5.3 (± 1.4) 1.5 (± 0.2)
293T - (+) - - 6.5 (± 1.9) 5.3 (± 0.4) 1.2 (± 0.2)
H-2171 + - (+) - 6.0 (± 0.5) 8.0 (± 1.0) 1.2 (± 0.2)
MDA-MB-468 - + (+) - 5.8 (± 1.8) 2.5 (± 0.7) 0.7 (± 0.7)
HL-60 (+) ++ - - 5.3 (± 1.2) 6.0 (± 1.0) 0.7 (± 0.2)
U937 (+) ++ - - 5.2 (± 0.9) 7.3 (± 3.3) 1.1 (± 1.2)
U2OS (+) (+) - - 4.9 (± 1.1) 3.3 (± 0.5) 1.2 (± 0.7)
NCI-H295 - (+) - - 4.7 (± 0.4) 3.0 (± 0.4) 0.3 (± 0.5)
KASUMI-1 (+) + - - 2.9 (± 0.2) 2.3 (± 1.4) 0.7(± 0.9)
Cell lines are lined up starting with highest rate of centrosomal abnormalities. +: high expression; (+): intermediate expression; -: Low expressiono rn o t
detectable.
Manthey et al. BMC Cell Biology 2010, 11:2
http://www.biomedcentral.com/1471-2121/11/2
Page 6 of 11overexpression may lead to stabilization of Aurora A by
interaction with the anaphase-promoting complex coac-
tivator Cdh1 [20]. Thus, high levels of ID1 may interact
with Cdh1 to stabilize Aurora-A and induce supernu-
merary centrosomes. The interactions between Aurora
kinases and ID1 require further functional in vitro ana-
lyses. Aurora-A is differentially regulated and expressed
in chromosomal and microsatellite instable colorectal
carcinomas and the observed high ID1 expression may
contribute to this [66-68]. Recent efforts of therapeutic
intervention with small molecule inhibitors of Aurora
kinase are ongoing, and the data presented here may
provide additional information about the potential ther-
apeutic mechanisms [69-71].
We did not observe a correlation between aneuploidy
and increased abnormal centrosomes. Nearly all cell
lines analyzed had aneuploid karyotypes (Additional File
3) but not all of them are characterized by high levels of
centrosome abnormalities. Even the rate of aneuploidy
does not seem to influence the frequency of abnormal
Figure 4 Statistical data evaluation. A) Logarithmic ID1 expression data compared with number of centrosomal abnormalities; B) Spearman’s
rank correlation coefficient r looking at ID expression and centrosome abnormalities: r values above, p values below; r = 1 shows perfect
correlation, r = 0 shows no correlation, 1> r > 0 shows positive correlation, in this case e.g. ID1 and centrosomal abnormalities.
Manthey et al. BMC Cell Biology 2010, 11:2
http://www.biomedcentral.com/1471-2121/11/2
Page 7 of 11centrosomes as MCF-7 and MDA-MB453 reveal only
slightly elevated levels of abnormal centrosomes accom-
panying aneuploidy. Altered p53 function contributes to
impaired centrosome function. Only four of the cell
lines used (T47-D, MCF-7, U2OS, Kasumi-1) have wild
type p53, whereas all other cell lines harbor a mutated
or inactivated p53 gene (Additional File 3). We failed to
see an influence of p53 status on steady state centro-
some numbers. As previously shown, ID1 appears to act
independent of p53 as it is able to induce centrosomal
abnormalities in p53 deficient as well as in p53 positive
cells [18].
Conclusions
Taken together we show here that not only ectopic but
also endogenous ID1 expression can deregulate centro-
some duplication, further supporting an oncogenic role
for this ID protein. This is in so far of importance, as
most knowledge about the function of ID proteins
comes from overexpression experiments, in which non-
physiologically high expression levels were used to
achieve biological effects. Furthermore, when evaluating
ID expression in tumors and cell lines, protein levels
should be analyzed and correlated with mRNA expres-
sion. Our results might imply that protein expression of
the IDs is more complex than previously thought and
that protein expression and not mRNA-expression
should be the main focus of further expression analysis
in primary tumors.
Methods
Cell culture
Cell lines used were HL-60, Jurkat, U937, Kasumi-1,
S i H a ,H e L a ,C a S k i ,C 3 3 A ,M D A - M B 4 6 8 ,M D A - M B 4 5 3 ,
T47-D, MCF-7, HaCaT, U2OS, 293T, NCIH295, HCT-
15 and H-2171. L-60, Jurkat, U937, Kasumi-1, MDA-
MB453, MCF-7, HCT-15, and H-2171 were maintained
in RPMI 1640 medium. NCIH295 cells were grown in
RPMI 1640 medium supplemented with 1% insuline-
transferrine-selenium-solution. All cervical cancer cell
lines (SiHa, HeLa, CaSki, C33A), and T47-D, MDA-
MB468, 293T, HaCaT, and U2OS were grown in D-
MEM. Medium was supplemented with an antibiotic-
antimycotic mixture (streptomycin, penicillin) and 10%
(vol/vol) or 15% (NCIH295) heat-inactivated fetal bovine
serum. Cells were grown at 37°C, 5% CO2 and 95%
vapor-saturated atmosphere.
Plasmids
Vectors used were pCMV-ID1 (p1121), pCMV-ID2
(p1122), pCMV-ID3 (p1123), pCMV-ID4 (p1124) [2].
Transfection
U2OS cells were transfected with Fugene 6 (Boehringer
Mannheim) according to the manufacturers directions.
Cells were harvested for analysis 48 h after transfection.
Cell harvesting and Western Blotting
Cell lines were grown in 100-mm tissue culture plates to
approximately 70% confluence and harvested. After
three washes with ice-cold PBS (Gibco) cells were lysed
with 100 to 250 μl of lysis buffer (0,5% NP-40 lysis buf-
fer, 50 mM Tris HCl pH 7,4, 150 mM NaCl, and pro-
tease and phosphatase inhibitors). Cell lysates were
clarified by centrifugation and quantitated by the Bio-
Rad DC protein assay system. Samples were then boiled
in SDS sample buffer, and equal amounts of proteins
were separated by SDS-polyacrylamide gel electrophor-
esis with 15% acrylamide and transferred to Hybond P
membranes (Amersham) for Western blotting analysis.
Primary antibodies used included Id1 (C-20), ID2 (C-
20), Id3 (H-70), ID4 (H-70) and GAPDH (FL-335)
( S a n t aC r u z ,S a n t aC r u z ,C A ,U S A ) .B o u n dp r o t e i n s
were detected with horseradish peroxidase-conjugated
secondary antibodies (Santa Cruz, Santa Cruz, CA,
USA). After extensive washing of the membrane, fluor-
escent signal was detected by ECL reagent (Amersham,
Braunschweig, Germany), followed by exposure to film
(Amersham Hyperfilm ECL, Braunschweig, Germany).
Image J program
Image J software (Wayne Rasband, National Institute of
Mental Health, Bethesda, Maryland, USA) was used to
evaluate protein expression. ID expression was normal-
ized to GAPDH expression in each cell line.
Immunofluorescence
Cells were grown on cover slips to a confluence of 70%,
washed with ice-cold PBS and fixed with methanol for
20 minutes at -20°C. After preincubation with normal
goat serum for 20 minutes at room temperature to
block unspecific protein binding, cells were incubated
with primary antibody g-Tubulin (Sigma, Deisenhofen,
Germany) overnight at -4°C. On the next day the cells
were incubated for 2 hours with secondary antibody
Alexa Fluor 488 (goat-anti-rabbit) (Molecular Probes,
Eugene, Oregon, USA) at 37,0°C in a humid chamber.
After visualization of nuclei using Hoechst 33258, cover
slips were mounted to microscope slides and analyzed
using a Zeiss Axioplan confocal microscope. Only
mononuclear (i.e. cells containing only one nucleus)
cells were analyzed for centrosome number and rate of
abnormal mitoses. A minimum of 15 high power fields
with at least 20 cells per field was analyzed per cell line.
To visualize ID-proteins the above mentioned antibodies
were used (1:100 dilution in PBS), then fluorescence
labeled secondary antibody Alexa Fluor 568 (Molecular
Probes, Eugene, Oregon, USA) was applied (1:200 dilu-
tion in PBS).
RNA isolation
Cells were grown in 100 mm-tissue culture plates to
70% confluence and total RNA was isolated with the
RNeasy MicroKit (Qiagen) according to the
Manthey et al. BMC Cell Biology 2010, 11:2
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was assessed by spectrophotometry.
Real-time PCR
Primer pairs (ID1 Forward: 5’ TCC AGC ACG TCG
ACT ACA 3’,I D 1R e v e r s e :5 ’ GGG TTC CAA CTT
CGG ATT CC 3’,I D 1P r o b e :5 ’ 6-Fam CAG GGA CCT
TCA GTT GG MGB 3’; ID2 Forward: 5’ CCA CCC
TCA ACA CGG ATA TCA 3’,I D 2R e v e r s e :5 ’ CAC
AGT GCT TTG CTG TCA TTT G 3’,I D 2P r o b e :5 ’ 6-
Fam TGT CCT TGC AGG CTT CTG MGB 3’;I D 3
Forward: 5’ CCC CAC CTT CCC ATC CA 3’,I D 3
Reverse: 5’ CAG TGG CAA AAG CTC CTT TTG 3’,
ID3 Probe: 5’ 6-Fam GAC AGC CGA GCT CAC MGB
3’; ID4 Forward: 5’ TCC CGC CCA ACA AGA AAG 3’,
ID4 Reverse: 5’ GGT CCA GGA TGT AGT CGA TAA
CG 3’, ID4 Probe: 5’ 6-Fam AGC AAA GTG GAG ATC
C MGB 3’ were designed using Primer Express (Applied
Biosystems). Quantitative reverse transcription-PCR was
performed on DNase-treated RNA using the TaqMan
Assay (Applied Biosystems) according to the manufac-
turer’s directions. Amplification of target sequences was
detected with an ABI 7000 sequence detection system
(Applied Biosystems) and analyzed with SDS 2.0 soft-
ware (Applied Biosystems). The cycle threshold (Ct) was
determined as the number of PCR cycles required for a
given reaction to reach an arbitrary fluorescence value
within the linear amplification range. Relative quantifica-
tion was performed according to the 2
-ΔΔCt method [72],
with GAPDH serving as reference and ID1-4 as target
genes. First, target and reference CT-values were sub-
tracted from each other (ΔCT) for each sample, fol-
lowed by subtraction of ΔCT-values of the cell line
samples from the reference (SiHa cell line) sample yield-
ing ΔΔCT and final calculation of the fold change by 2
-
ΔΔCt.
FACS analysis
Cellular DNA content and cell cycle distribution was
measured using a Dako Cytomation FACS sorter. After
trypsinization cells were pelleted and fixed with 100%
ethanol over night. The following day cells were incu-
bated with RNAse A and Propidium iodide for 30 min-
utes and then subjected to FACS.
Statistical analysis
Data are provided as mean ± SEM. To determine the
correlation between centrosomal abnormalities and ID
expression Pearson’s correlation coefficient and Spear-
man’s coefficient were calculated following the conver-
sion of ID expression data into logarithmic values.
Furthermore r-square was determined to distinguish
whether centrosomal abnormalities could be explained
by changes of ID expression.
Additional file 1: FACS analysis of SiHa, MCF-7, and T47-D cell lines.
DNA content of the cells was evaluated using FACS sorting (Dako
Cytomation) after cells were treated with RNAse and Propidium iodide.
Representative example of A) SiHa, B) MCF-7 and C) T47-D DNA content
(64 corresponds to a single set of chromosomes (G1, G0), 128 to a
doubled set of chromosomes (G2), counts in between show cells in S
phase.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2121-11-2-
S1.EPS]
Additional file 2: Comparison of HL-60 and Jurkat leukemic cell
lines. A) Co-Immunofluorescence analysis subcellular localization of ID1
and g-tubulin; nuclei were visualized using Hoechst 33258 (blue). B)
Quantitative analysis of cells with n > 2 centrosomes and percent mitotic
cells (mean of at least 3 independent experiments, ± standard deviation).
C) ID1 protein expression in HL-60 and Jurkat cells. Protein extracts (10
μg) were analyzed by immuno blotting using primary antibodies against
ID1 (C-20), and GAPDH (loading control).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2121-11-2-
S2.EPS]
Additional file 3: Table. Characteristics of cell lines used.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2121-11-2-
S3.DOC]
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